Program
erfonrilimab
Also written as “KN046”, “GT90001+KN046” and “KN046 (PD-L1/CTLA4 BsAb)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Thymoma · Lymphoma · Triple Negative Breast Neoplasms, led by 4 companies.
Drug pageErfonrilimab: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alphamab Oncologyits history only | 111 open or running | phase 3since Jul 13, 2020 | May 8, 2018 | none ahead |
| Suzhou Kintor Pharmaceutical | 11 open or running | phase 2since Jul 5, 2021 | Jul 5, 2021 | none ahead |
| Suzhou Zelgen Biopharmaceuticalsits history only | 10 open or running | phase 2since Oct 29, 2020 | Oct 29, 2020 | none ahead |
| Zhejiang Raygene Pharmaceuticalsits history only | 10 open or running | phase 2since Feb 13, 2025 | Feb 13, 2025 | none ahead |
Also a collaborator on its studies: Sunshine Lake Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Suzhou Kintor Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named erfonrilimabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, KN046
- Jul 5, 2021First study: phase 2 study in Solid TumorFirst studyNCT04984668 · 216 planned · Taiwan
TargetBeta
“A bispecific monoclonal antibody directed against both the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Studies
The one study Suzhou Kintor Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04984668Solid Tumor · Taiwan | 2 | Recruiting | Apr 2025 | 216 |
How it is read
Names in the registry
- “KN046”, 11 entries
- “GT90001+KN046”, 4 entries
- “KN046 (PD-L1/CTLA4 BsAb)”, 2 entries
- “KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)”, 1 entry
- “KN046 Injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Colorectal Neoplasms, 1 study
- Thymoma, 1 study
- Lymphoma, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.